China's self-developed H7N9 avian influenza vaccine enters clinical trial

July 02, 2021

Li Lanjuan, member of the National Committee of the Chinese People's Political Consultative Conference and academician of the Chinese Academy of Engineering, said that the H7N9 avian Influenza Vaccine developed by China has been sent to the National Institute of Pharmaceutical and Biological Products for verification.

Li Lanjuan said that the human infection with the H7N9 avian influenza virus Vaccine strain was completely developed by our country, which for the first time broke and changed the history of China's influenza vaccine strain that needs to be provided by foreign countries. As for the use of the vaccine, Li Lanjuan believes that it is not necessary to blindly vaccinate because of panic, but people who need to contact more poultry can be vaccinated for prevention.

(Source: People's Daily)

The above is the China's self-developed H7N9 avian influenza vaccine enters clinical trial we have listed for you. You can submit the following form to obtain more industry information we provide for you.

You can visit our website or contact us, and we will provide the latest consultation and solutions

Share to:

Send Inquiry

Previou:China's State Food and Drug Administration approved the "human-use pickup rabies vaccine" project to carry out phase III clinical trials

Next:Regulations on the manufacture and verification of human concentrated rabies vaccine

Most Popular

China's State Food and Drug Administration approved the "human-use pickup rabies vaccine" project to carry out phase III clinical trials

China's self-developed H7N9 avian influenza vaccine enters clinical trial

Regulations on the manufacture and verification of human concentrated rabies vaccine

Mechanism of influenza vaccine activating protective immune response

Send Inquiry